From amino acids to proteins as targets for metal-based drugs

Current Drug Metabolism

Volumn 13, Issue 3, 2012, Pages 306-320

  Zitka, Ondrej ^a,b   Ryvolova, Marketa ^a,b   Hubalek, Jaromir ^b   Eckschlager, Tomas ^c   Adam, Vojtech ^a,b   Kizek, Rene ^a,b  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Amino acid; Interactions; Metallomics; Metals; Nanotechnology; Peptide; Protein

Indexed keywords

AMINO ACID; ANTIMONY; ARSENIC; ARSENIC TRIOXIDE; BERYLLIUM; BISMUTH; CADMIUM; CALCIUM; CARBOPLATIN; CHROMIUM; CISPLATIN; COBALT; COPPER; IRON; LANTHANUM CARBONATE; LEAD; MANGANESE; MERCURY; METAL ION; MOLYBDENUM; NICKEL; OXALIPLATIN; PLATINUM COMPLEX; RUTHENIUM; SELENIUM; SILVER; TIN; TUNGSTEN; VANADIUM; ZINC;

ARGYRIA; ARSENIC POISONING; ARTICLE; BLOOD BRAIN BARRIER; DNA DETERMINATION; DNA STRUCTURE; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HYPERPHOSPHATEMIA; IN VIVO STUDY; INTOXICATION; LD 50; LIPID METABOLISM; LUNG CANCER; MOLECULAR IMAGING; MOLECULAR INTERACTION; NANOBIOTECHNOLOGY; NEPHROTOXICITY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; OPTICALLY STIMULATED LUMINESCENCE; OTOTOXICITY; POSITRON EMISSION TOMOGRAPHY; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN INTERACTION; RNA ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURAL GENOMICS; ULTRASOUND; VOMITING;

AMINO ACIDS; ANIMALS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; HUMANS; METALLOPROTEINS; METALS; NANOTECHNOLOGY; PROTEINS;

EID: 84860503407     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012799320437     Document Type: Article

References (252)

1. Scott, L. E.; Orvig, C. Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease. Chem. Rev., 2009, 109 10, 4885-4910.
2. Szpunar, J. Metallomics: a new frontier in analytical chemistry. Anal. Bioanal. Chem., 2004, 378 1, 54-56.
3. Haraguchi, H. Metallomics as integrated biometal science. J. Anal. At. Spectrom., 2004, 19 1, 5-14.
4. Chance, M. R.; Fiser, A.; Sali, A.; Pieper, U.; Eswar, N.; Xu, G. P.; Fajardo, J. E.; Radhakannan, T.; Marinkovic, N. High-throughput computational and experimental techniques in structural genomics. Genome Res., 2004, 14(10B), 2145-2154.
5. Williams, R. J. P. Chemical selection of elements by cells. Coord. Chem. Rev., 2001, 216, 583-595.
6. Shi, W.; Chance, M. R. Metallomics and metalloproteomics. Cell. Mol. Life Sci., 2008, 65 19, 3040-3048.
7. Tainer, J. A.; Roberts, V. A.; Getzoff, E. D. Metal-Binding Sites in Proteins. Curr. Opin. Biotechnol., 1991, 2 4, 582-591.
8. Degtyarenko, K. Bioinorganic motifs: towards functional classification of metalloproteins. Bioinformatics, 2000, 16 10, 851-864.
9. Shi, W. X.; Zhan, C. Y.; Ignatov, A.; Manjasetty, B. A.; Marinkovic, N.; Sullivan, M.; Huang, R.; Chance, M. R. Metalloproteomics: High-throughput structural and functional annotation of proteins in structural genomics. Structure, 2005, 13 10, 1473-1486.
10. Andreini, C.; Banci, L.; Bertini, I.; Rosato, A. Zinc through the three domains of life. J. Proteome Res., 2006, 5 11, 3173-3178.
11. Kryukov, G. V.; Castellano, S.; Novoselov, S. V.; Lobanov, A. V.; Zehtab, O.; Guigo, R.; Gladyshev, V. N. Characterization of mammalian selenoproteomes. Science, 2003, 300 5624, 1439-1443.
12. Fairweather-Tait, S. J.; Bao, Y. P.; Broadley, M. R.; Collings, R.; Ford, D.; Hesketh, J. E.; Hurst, R. Selenium in Human Health and Disease. Antioxid. Redox Signal., 2011, 14 7, 1337-1383.
13. Novotny, L.; Rauko, P.; Kombian, S. B.; Edafiogho, I. O. Selenium as a chemoprotective anti-cancer agent: Reality or wishful thinking? Neoplasma, 2010, 57 5, 383-391.
14. Papp, L. V.; Lu, J.; Holmgren, A.; Khanna, K. K. From selenium to selenoproteins: Synthesis, identity, and their role in human health. Antioxid. Redox Signal., 2007, 9 7, 775-806.
15. Selenius, M.; Rundlof, A. K.; Olm, E.; Fernandes, A. P.; Bjornstedt, M. Selenium and the Selenoprotein Thioredoxin Reductase in the Prevention, Treatment and Diagnostics of Cancer. Antioxid. Redox Signal., 2010, 12 7, 867-880.
16. Zimmermann, S.; Sures, B. Significance of platinum group metals emitted from automobile exhaust gas converters for the biosphere. Environ. Sci. Pollut. Res., 2004, 11 3, 194-199.
17. Carmona, A.; Deves, G.; Ortega, R. In 14th Conference on Solid State Analysis; Springer Heidelberg: Vienna, AUSTRIA, 2007, pp 1585-1594.
18. Bush, A. I. The metallobiology of Alzheimer's disease. Trends Neurosci., 2003, 26 4, 207-214.
19. Gupta, V. B.; Anitha, S.; Hegde, M. L.; Zecca, L.; Garruto, R. M.; Ravid, R.; Shankar, S. K.; Stein, R.; Shanmugavelu, P.; Rao, K. S. J. Aluminium in Alzheimer's disease: are we still at a crossroad? Cell. Mol. Life Sci., 2005, 62 2, 143-158.
20. McRae, R.; Bagchi, P.; Sumalekshmy, S.; Fahrni, C. J. In Situ Imaging of Metals in Cells and Tissues. Chem. Rev., 2009, 109 10, 4780-4827.
21. Raymond, E.; Faivre, S.; Chaney, S.; Woynarowski, J.; Cvitkovic, E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther., 2002, 1 3, 227-235.
22. Raymond, E.; Chaney, S. G.; Taamma, A.; Cvitkovic, E. Oxaliplatin: A review of preclinical and clinical studies. Ann. Oncol., 1998, 9 10, 1053-1071.
23. Fuertes, M. A.; Castilla, J.; Alonso, C.; Perez, J. M. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem., 2003, 10 3, 257-266.
24. Ong, S. T.; Vogelzang, N. J. Chemotherapy in malignant pleural mesothelioma: A review. J. Clin. Oncol., 1996, 14 3, 1007-1017.
25. Weiss, R. B.; Christian, M. C. New Cisplatin Analogs in Development - a Review. Drugs, 1993, 46 3, 360-377.
26. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-699.
27. Go, R. S.; Adjei, A. A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol., 1999, 17 1, 409-422.
28. See, H. T.; Freedman, R. S.; Kudelka, A. P.; Burke, T. W.; Gershenson, D. M.; Tangjitgamol, S.; Kavanagh, J. J. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int. J. Gynecol. Cancer, 2005, 15 2, 209-216.
29. Dy, G. K.; Bruzek, L. M.; Croghan, G. A.; Mandrekar, S.; Erlichman, C.; Peethambaram, P.; Pilot, H. C.; Hanson, L. J.; Reid, J. M.; Furth, A.; Cheng, S.; Martell, R. E.; Kaufmann, S. H.; Adjei, A. A. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin. Cancer Res., 2005, 11 5, 1877-1883.
30. Grothey, A.; Goldberg, R. M. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin. Pharmacol., 2004, 5 10, 2159-2170.
31. Arango, D.; Wilson, A. J.; Shi, Q.; Corner, G. A.; Aranes, M. J.; Nicholas, C.; Lesser, M.; Mariadason, J. M.; Augenlicht, L. H. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Brit. J. Cancer, 2004, 91 11, 1931-1946.
32. Zak, F.; Turanek, J.; Kroutil, A.; Sova, P.; Mistr, A.; Poulova, A.; Mikolin, P.; Zak, Z.; Kasna, A.; Zaluska, D.; Neca, J.; Sindlerova, L.; Kozubik, A. Platinum (IV) complex with adamantylamine as nonleaving amine group: Synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J. Med. Chem., 2004, 47 3, 761-763.
33. Sova, P.; Chladek, J.; Zak, F.; Mistr, A.; Kroutil, A.; Semerad, M.; Slovak, Z. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43) bis (acetato) (1-adamantylamine) amminedichloroplatinum (IV)]. Int. J. Pharm., 2005, 288 1, 123-129.
34. Kozubik, A.; Horvath, V.; Svihalkova-Sindlerova, L.; Soucek, K.; Hofmanova, J.; Sova, P.; Kroutil, A.; Zak, F.; Mistr, A.; Turanek, J. High effectiveness of platinum (IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem. Pharmacol., 2005, 69 3, 373-383.
35. Ramos-Lima, F. J.; Vrana, O.; Quiroga, A. G.; Navarro-Ranninger, C. N.; Halamikova, A.; Rybnickova, H.; Hejmalova, L.; Brabec, V. Structural characterization, DNA interactions, and cytotoxicity of new transplatin analogues containing one aliphatic and one planar heterocyclic amine ligand. J. Med. Chem., 2006, 49 8, 2640-2651.
36. Najajreh, Y.; Kasparkova, J.; Marini, V.; Gibson, D.; Brabec, V. Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand. J. Biol. Inorg. Chem., 2005, 10 7, 722-731.
37. Kukushkin, V. Y.; Oskarsson, A.; Elding, L. I.; Farrell, N.; Vicente, J.; Chicote, M. T.; Kauffman, G. B.; Houghten, R. A.; Likins, R. E.; Posson, P. L.; Ray, R. K. Transition metal complexes and precursors. Inorg. Synt., 1998, 32, 141-228.
38. Lemma, K.; House, D. A.; Retta, N.; Elding, L. I. Kinetics and mechanism for reduction of halo-and haloam (m) ine platinum (IV) complexes by L-ascorbate. Inorg. Chim. Acta, 2002, 331, 98-108.
39. Deeth, R. J.; Elding, L. I. Theoretical modeling of water exchange on Pd (H2O) (4) (2+), Pt (H2O) (4) (2+), and trans-PtCl2 (H2O) (2). Inorg. Chem., 1996, 35 17, 5019-5026.
40. Kartalou, M.; Essigmann, J. M. Mechanisms of resistance to cisplatin. Mutat. Res-Fund. Mol. M., 2001, 478(1-2), 23-43.
41. Kartalou, M.; Essigmann, J. M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res-Fund. Mol. M., 2001, 478(1-2), 1-21.
42. Chaney, S. G.; Campbell, S. L.; Temple, B.; Bassett, E.; Wu, Y. B.; Faldu, M. Protein interactions with platinum-DNA adducts: from structure to function. J. Inorg. Biochem., 2004, 98 10, 1551-1559.
43. Page, J. D.; Husain, I.; Sancar, A.; Chaney, S. G. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry, 1990, 29 4, 1016-1024.
44. Mani, S.; Graham, M. A.; Bregman, D. B.; Ivy, P.; Chaney, S. G. Oxaliplatin: A review of evolving concepts. Cancer Invest., 2002, 20 2, 246-263.
45. Woynarowski, J. M.; Chapman, W. G.; Napier, C.; Herzig, M. C. S.; Juniewicz, P. Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol., 1998, 54 5, 770-777.
46. Hall, M. D.; Failes, T. W.; Yamamoto, N.; Hambley, T. W. Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. Dalton Trans., 2007, 36, 3983-3990.
47. Ware, D. C.; Palmer, B. D.; Wilson, W. R.; Denny, W. A. Hypoxia-Selective Antitumor Agents.7. Metal-Complexes of Aliphatic Mustards as a New Class of Hypoxia-Selective Cytotoxins - Synthesis and Evaluation of Cobalt (Iii) Complexes of Bidentate Mustards. J. Med. Chem., 1993, 36 13, 1839-1846.
48. Carter, D. E.; Aposhian, H. V.; Gandolfi, A. J. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol. Appl. Pharmacol., 2003, 193 3, 309-334.
49. Thomas, D. J. In Int. Works. Res. Risk Ass. Arsen.; Academic Press Inc Elsevier Science: Shepherdstown, WV, 2006, pp 365-373.
50. Soignet, S. L.; Frankel, S. R.; Douer, D.; Tallman, M. S.; Kantarjian, H.; Calleja, E.; Stone, R. M.; Kalaycio, M.; Scheinberg, D. A.; Steinherz, P.; Sievers, E. L.; Coutre, S.; Dahlberg, S.; Ellison, R.; Warrell, R. P. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol., 2001, 19 18, 3852-3860.
51. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1 6, 458-470.
52. Schmid, W. F.; John, R. O.; Muhlgassner, G.; Heffeter, P.; Jakupec, M. A.; Galanski, M.; Berger, W.; Arion, V. B.; Keppler, B. K. Metalbased paullones as putative CDK inhibitors for antitumor chemotherapy. J. Med. Chem., 2007, 50 25, 6343-6355.
53. Urbano, A. M.; Rodrigues, C. F. D.; Alpoim, M. C. Hexavalent chromium exposure, genomic instability and lung cancer. Gene Ther. Mol. Biol., 2008, 12 B, 219-238.
54. Behets, G. J.; Verberckmoes, S. C.; D'Haese, P. C.; De Broe, M. E. Lanthanum carbonate: a new phosphate binder. Curr. Opin. Nephrol. Hypertens., 2004, 13 4, 403-409.
55. Kusakabe, T.; Nakajima, K.; Suzuki, K.; Nakazato, K.; Takada, H.; Satoh, T.; Oikawa, M.; Kobayashi, K.; Koyama, H.; Arakawa, K.; Nagamine, T. The changes of heavy metal and metallothionein distribution in testis induced by cadmium exposure. Biometals, 2008, 21 1, 71-81.
56. Bottrill, M.; Nicholas, L. K.; Long, N. J. Lanthanides in magnetic resonance imaging. Chem. Soc. Rev., 2006, 35 6, 557-571.
57. Cutler, C. S.; Smith, C. J.; Ehrhardt, G. J.; Tyler, T. T.; Jurisson, S. S.; Deutsch, E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother. Radiopharm., 2000, 15 6, 531-545.
58. O'Connor, J. P. B.; Naish, J. H.; Parker, G. J. M.; Waterton, J. C.; Watson, Y.; Jayson, G. C.; Buonaccorsi, G. A.; Cheung, S.; Buckley, D. L.; McGrath, D. M.; West, C. M. L.; Davidson, S. E.; Roberts, C.; Mills, S. J.; Mitchell, C. L.; Hope, L.; Ton, C.; Jackson, A. Preliminary Study of Oxygen-Enhanced Longitudinal Relaxation in Mri: a Potential Novel Biomarker of Oxygenation Changes in Solid Tumors. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75 4, 1209-1215.
59. Ma, Z.; Jacobsen, F. E.; Giedroc, D. P. Coordination Chemistry of Bacterial Metal Transport and Sensing. Chem. Rev., 2009, 109 10, 4644-4681.
60. Sanchez, L.; Aranda, P.; Perez, M. D.; Calvo, M. Concentration of Lactoferrin and Transferrin Throughout Lactation in Cows Colostrum and Milk. Biol. Chem. Hoppe-Seyler, 1988, 369 9, 1005-1008.
61. Tsunoo, H.; Sussman, H. H. Characterization of Transferrin Binding and Specificity of the Placental Transferrin Receptor. Arch. Biochem. Biophys., 1983, 225 1, 42-54.
62. Anderson, G. J.; Vulpe, C. D. Mammalian iron transport. Cell. Mol. Life Sci., 2009, 66 20, 3241-3261.
63. Rolfs, A.; Hediger, M. A. Metal ion transporters in mammals: structure, function and pathological implications. J. Physiol.-London, 1999, 518 1, 1-12.
64. Ellis, C. D.; MacDiarmid, C. W.; Eide, D. J. Heteromeric protein complexes mediate zinc transport into the secretory pathway of eukaryotic cells. J. Biol. Chem., 2005, 280 31, 28811-28818.
65. Gaither, L. A.; Eide, D. J. Eukaryotic zinc transporters and their regulation. Biometals, 2001, 14(3-4), 251-270.
66. Aller, S. G.; Eng, E. T.; De Feo, C. J.; Unger, V. M. Eukaryotic CTR copper uptake transporters require two faces of the third transmembrane domain for helix packing, oligomerization, and function. J. Biol. Chem., 2004, 279 51, 53435-53441.
67. Kaplan, J. H.; Lutsenko, S. Copper Transport in Mammalian Cells: Special Care for a Metal with Special Needs. J. Biol. Chem., 2009, 284 38, 25461-25465.
68. Terada, K.; Schilsky, M. L.; Miura, N.; Sugiyama, T. ATP7B (WND) protein. Int J. Biochem. Cell Biol., 1998, 30 10, 1063-1067.
69. Vidal, S.; Belouchi, A. M.; Cellier, M.; Beatty, B.; Gros, P. Cloning and Characterization of a 2nd Human Nramp Gene on Chromosome-12q13. Mamm. Genome, 1995, 6 4, 224-230.
70. Lage, H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents, 2003, 22 3, 188-199.
71. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res., 2001, 42 7, 1007-1017.
72. Ballatori, N.; Krance, S. M.; Marchan, R.; Hammond, C. L. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol. Asp. Med., 2009, 30(1-2), 13-28.
73. Leslie, E. M.; Deeley, R. G.; Cole, S. P. C. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology, 2001, 167 1, 3-23.
74. Niegowski, D.; Eshaghi, S. The CorA family: Structure and function revisited. Cell. Mol. Life Sci., 2007, 64(19-20), 2564-2574.
75. Bridges, C. C.; Zalups, R. K. Molecular and ionic mimicry and the transport of toxic metals. Toxicol. Appl. Pharmacol., 2005, 204 3, 274-308.
76. Jacobson, K. B.; Turner, J. E. The Interaction of Cadmium and Certain Other Metal-Ions with Proteins and Nucleic-Acids. Toxicology, 1980, 16 1, 1-37.
77. Au, C.; Benedetto, A.; Aschner, M. Manganese transport in eukaryotes: The role of DMT1. Neurotoxicology, 2008, 29 4, 569-576.
78. O'Halloran, T. V.; Culotta, V. C. Metallochaperones, an intracellular shuttle service for metal ions. J. Biol. Chem., 2000, 275 33, 25057-25060.
79. Ba, L. A.; Doering, M.; Burkholz, T.; Jacob, C. Metal trafficking: from maintaining the metal homeostasis to future drug design. Metallomics, 2009, 1 4, 292-311.
80. Jambor, A.; Molnar-Perl, I. Quantitation of amino acids in plasma by high performance liquid chromatography: Simultaneous deproteinization and derivatization with 9-fluorenylmethyloxycarbonyl chloride. J. Chromatogr. A, 2009, 1216 34, 6218-6223.
81. Carratu, B.; Boniglia, C.; Agostoni, C.; Gamboni, A.; Mugnoli, S.; Lammardo, A.; Sanzini, E.; Riva, E. Free aminoacid content in human milk in the first three months of lactation. Riv. Ital. Pediatr. Ital. J. Pediatr., 1998, 24 5, 1013-1016.
82. Agostoni, C.; Carratu, B.; Boniglia, C.; Riva, E.; Sanzini, E. Comparative free amino acid profiles of human milk and some infant formulas sold in Europe - Response. J. Am. Coll. Nutr., 2001, 20 1, 92-93.
83. Watkins, D.; Ru, M.; Hwang, H. Y.; Kim, C. D.; Murray, A.; Philip, N. S.; Kim, W.; Legakis, H.; Wai, T.; Hilton, J. F.; Ge, B.; Dore, C.; Hosack, A.; Wilson, A.; Gravel, R. A.; Shane, B.; Hudson, T. J.; Rosenblatt, D. S. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: Structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am. J. Hum. Genet., 2002, 71 1, 143-153.
84. Giles, N. M.; Giles, G. I.; Jacob, C. Multiple roles of cysteine in biocatalysis. Biochem. Biophys. Res. Commun., 2003, 300 1, 1-4.
85. Simmons-Willis, T. A.; Koh, A. S.; Clarkson, T. W.; Ballatori, N. Transport of a neurotoxicant by molecular mimicry: the methylmercury-L-cysteine complex is a substrate for human L-type large neutral amino acid transporter (LAT) 1 and LAT2. Biochem. J., 2002, 367, 239-246.
86. Guo, Y.; Smith, K.; Petris, M. J. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter - Requirement for the extracellular methionine-rich clusters. J. Biol. Chem., 2004, 279 45, 46393-46399.
87. Rees, E. M.; Lee, J.; Thiele, D. J. Mobilization of intracellular copper stores by the Ctr2 vacuolar copper transporter. J. Biol. Chem., 2004, 279 52, 54221-54229.
88. Selhub, J. Homocysteine metabolism. Annu. Rev. Nutr., 1999, 19, 217-246.
89. Treskes, M.; Holwerda, U.; Nijtmans, L. G. J.; Pinedo, H. M.; Vandervijgh, W. J. F. The Reversal of Cisplatin-Protein Interactions by the Modulating Agent Wr2721 and Its Metabolites Wr1065 and Wr33278. Cancer Chemother. Pharmacol., 1992, 29 6, 467-470.
90. Bierbach, U.; Farrell, N. Structural and reactivity studies on the ternary system guanine/methionine/trans-[PtCl2 (NH3) L] (L = NH3, quinoline): implications for the mechanism of action of nonclassical trans-platinum antitumor complexes. J. Biol. Inorg. Chem., 1998, 3 6, 570-580.
91. Reedijk, J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev., 1999, 99 9, 2499-2510.
92. Beltran, M.; Onoa, G. B.; Pedroso, E.; Moreno, V.; Grandas, A. Study of the interaction between a histidine-deoxyguanosine hybrid and cisplatin. J. Biol. Inorg. Chem., 1999, 4 6, 701-707.
93. Hahn, M.; Kleine, M.; Sheldrick, W. S. Interaction of cisplatin with methionine-and histidine-containing peptides: competition between backbone binding, macrochelation and peptide cleavage. J. Biol. Inorg. Chem., 2001, 6(5-6), 556-566.
94. Saudek, V.; Pivcova, H.; Noskova, D.; Drobnik, J. The Reaction of Pt-Antitumor Drugs with Selected Nucleophiles. 2. Preparation and Characterization of Coordination-Compounds of Pt (Ii) and LHistidine. J. Inorg. Biochem., 1985, 23 1, 55-72.
95. Appleton, T. G.; Pesch, F. J.; Wienken, M.; Menzer, S.; Lippert, B. Linkage Isomerism in Square-Planar Complexes of Platinum and Palladium with Histidine and Derivatives. Inorg. Chem., 1992, 31 21, 4410-4419.
96. Nair, P. S.; Robinson, W. E. Purification and characterization of a histidine-rich glycoprotein that binds cadmium from the blood plasma of the bivalve Mytilus edulis. Arch. Biochem. Biophys., 1999, 366 1, 8-14.
97. Appleton, T. G.; Hall, J. R.; Neale, D. W.; Thompson, C. S. M. Reactions of the Cis-Diamminediaquaplatinum (Ii) Cation with 2-Aminomalonic Acid and Its Homologs, Aspartic and Glutamic Acids - Rearrangements of Metastable Complexes with Carboxylate-Bound Ligands to N, O-Chelates and Formation of Dinuclear and Trinuclear Complexes. Inorg. Chem., 1990, 29 20, 3985-3990.
98. Miller, S. E.; House, D. A. The Hydrolysis Products of Cis-Diamminedichloroplatinum (Ii).5. the Anation Kinetics of Cis-Pt (X) (Nh3) 2 (Oh2) + (X = Cl, Oh) with Glycine, Monohydrogen Malonate and Chloride. Inorg. Chim. Acta, 1991, 187 2, 125-132.
99. Kushev, D.; Gorneva, G.; Enchev, V.; Naydenova, E.; Popova, J.; Taxirov, S.; Maneva, L.; Grancharov, K.; Spassovska, N. Synthesis, cytotoxicity, antibacterial and antitumor activity of platinum (II) complexes of 3-aminocyclohexanespiro-5-hydantoin. J. Inorg. Biochem., 2002, 89(3-4), 203-211.
100. Zimmermann, T.; Zeizinger, M.; Burda, J. V. Cisplatin interaction with cysteine and methionine, a theoretical DFT study. J. Inorg. Biochem., 2005, 99 11, 2184-2196.
101. Sovago, I.; Osz, K. Metal ion selectivity of oligopeptides. Dalton Trans., 2006(32), 3841-3854.
102. Kozlowski, H.; Kowalik-Jankowska, T.; Jezowska-Bojczuk, M. Chemical and biological aspects of Cu2+ interactions with peptides and aminoglycosides. Coord. Chem. Rev., 2005, 249(21-22), 2323-2334.
103. Kozlowski, H.; Bal, W.; Dyba, M.; Kowalik-Jankowska, T. Specific structure-stability relations in metallopeptides. Coord. Chem. Rev., 1999, 184, 319-346.
104. Kallay, C.; Turi, I.; Timari, S.; Nagy, Z.; Sanna, D.; Pappalardo, G.; de Bona, P.; Rizzarelli, E.; Imre, S. The effect of point mutations on copper (II) complexes with peptide fragments encompassing the 106-114 region of human prion protein. Mon. Chem., 2011, 142 4, 411-419.
105. Matera-Witkiewicz, A.; Brasun, J.; Cebrat, M. Interactions between Ni2+ ions and tetrapeptides containing (Asp/Lys) HisGly (L/D) His sequence. Polyhedron, 2010, 29 16, 3052-3058.
106. Murariu, M.; Popa, K.; Dragan, E. S.; Drochioiu, G. Synthetic cysteine-peptide and its relation with heavy and radioactive metals. Rev. Roum. Chim., 2009, 54 9, 741-747.
107. Berezovskaya, Y.; Armstrong, C. T.; Boyle, A. L.; Porrini, M.; Woolfson, D. N.; Barran, P. E. Metal binding to a zinc-finger peptide: a comparison between solution and the gas phase. Chem. Commun., 2011, 47 1, 412-414.
108. Hultberg, B.; Andersson, A.; Isaksson, A. Interaction of metals and thiols in cell damage and glutathione distribution: potentiation of mercury toxicity by dithiothreitol. Toxicol., 2001, 156(2-3), 93-100.
109. Delalande, O.; Desvaux, H.; Godat, E.; Valleix, A.; Junot, C.; Labarre, J.; Boulard, Y. Cadmium - glutathione solution structures provide new insights into heavy metal detoxification. FEBS J., 2010, 277 24, 5086-5096.
110. Hayes, J. D.; Pulford, D. J. The glutathione S-Transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol., 1995, 30 6, 445-600.
111. Sen, C. K.; Packer, L. Antioxidant and redox regulation of gene transcription. Faseb J., 1996, 10 7, 709-720.
112. Schafer, F. Q.; Buettner, G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med., 2001, 30 11, 1191-1212.
113. Noctor, G.; Foyer, C. H. Ascorbate and glutathione: Keeping active oxygen under control. Annu. Rev. Plant Physiol. Plant Mol. Biol., 1998, 49, 249-279.
114. Krezel, A.; Bal, W. Studies of zinc (II) and nickel (II) complexes of GSH, GSSG and their analogs shed more light on their biological relevance. Bioinorg. Chem. Appl., 2004, 2(3-4), 293-305.
115. Ferretti, L.; Elviri, L.; Pellinghelli, M. A.; Predieri, G.; Tegoni, M. Glutathione and N-acetylcysteinylglycine: Protonation and Zn2+ complexation. J. Inorg. Biochem., 2007, 101 10, 1442-1456.
116. Krezel, A.; Wojcik, J.; Maciejczyk, M.; Bal, W. May GSH and LHis contribute to intracellular binding of zinc? Thermodynamic and solution structural study of a ternary complex. Chem. Commun., 2003, (6), 704-705.
117. Krezel, A.; Szczepanik, W.; Sokolowska, M.; Jezowska-Bojczuk, M.; Bal, W. Correlations between complexation modes and redox activities of Ni (II)-GSH complexes. Chem. Res. Toxicol., 2003, 16 7, 855-864.
118. Joshi, S.; Husain, M. M.; Chandra, R.; Hasan, S. K.; Srivastava, R. C. Hydroxyl radical formation resulting from the interaction of nickel complexes of L-histidine, glutathione or L-cysteine and hydrogen peroxide. Hum. Exp. Toxicol., 2005, 24 1, 13-17.
119. Burford, N.; Eelman, M. D.; Groom, K. Identification of complexes containing glutathione with As (III), Sb (III), Cd (II), Hg (II), Tl (I), Pb (II) or Bi (III) by electrospray ionization mass spectrometry. J. Inorg. Biochem., 2005, 99 10, 1992-1997.
120. Fuhr, B. J.; Rabenste. Dl Nuclear magnetic-resonance studies of solution chemistry of metal-complexes.9. binding of cadmium, zinc, lead, and mercury by glutathione. J. Am. Chem. Soc., 1973, 95 21, 6944-6950.
121. Khan, H.; Jan, S. U.; Hashmatullah; Khan, M. F.; Khan, K. A.; Rehman, A. U.; Wahab, A. Effect of lithium metal on the chemical status of glutathione (gsh) present in whole blood (especially in plasma and cytosolic fraction in human blood). Pak. J. Pharm. Sci., 2010, 23 2, 188-193.
122. Ishikawa, T.; Aliosman, F. Glutathione-Associated Cis- Diamminedichloroplatinum (Ii) Metabolism and Atp-Dependent Efflux from Leukemia-Cells - Molecular Characterization of Glutathione-Platinum Complex and Its Biological Significance. J. Biol. Chem., 1993, 268 27, 20116-20125.
123. Kasherman, Y.; Sturup, S.; Gibson, D. Is Glutathione the Major Cellular Target of Cisplatin? A Study of the Interactions of Cisplatin with Cancer Cell Extracts. J. Med. Chem., 2009, 52 14, 4319-4328.
124. Xu, Y. Y.; Jiang, N.; Yu, H. M. Effect of glutathione combined with cisplatin and oxaliplatin on the proliferation and apoptosis of lung carcinoma cell line. Toxicol. Mech. Methods, 2010, 20 8, 487-492.
125. Zitka, O.; Huska, D.; Krizkova, S.; Adam, V.; Chavis, G. J.; Trnkova, L.; Horna, A.; Hubalek, J.; Kizek, R. An investigation of glutathione-platinum (II) interactions by means of the flow injection analysis using glassy carbon electrode. Sensors, 2007, 7 7, 1256-1270.
126. Kirin, S. I.; Ott, I.; Gust, R.; Mier, W.; Weyhermuller, T.; Metzler-Nolte, N. Cellular uptake quantification of metalated peptide and peptide nucleic acid bioconjugates by atomic absorption spectroscopy. Angew. Chem. Int. Edit., 2008, 47 5, 955-959.
127. Pei, K. L.; Sooriyaarachchi, M.; Sherrell, D. A.; George, G. N.; Gailer, J. Probing the coordination behavior of Hg2+, CH3Hg+, and Cd2+ towards mixtures of two biological thiols by HPLC-ICPAES. J. Inorg. Biochem., 2011, 105 3, 375-381.
128. Krezel, A.; Wojcik, J.; Maciejczyk, M.; Bal, W. Zn (II) Complexes of Glutathione Disulfide: Structural Basis of Elevated Stabilities. Inorg. Chem., 2011, 50 1, 72-85.
129. Al-Maythalony, B. A.; Wazeer, M. I. M.; Isab, A. A. H-1, C-13 NMR and UV spectroscopy studies of gold (III)-tetracyanide complex with L-cysteine, glutathione, captopril, L-methionine and DLselenomethionine in aqueous solution. Inorg. Chim. Acta, 2010, 363 13, 3244-3253.
130. Chaga, G. S. Twenty-five years of immobilized metal ion affinity chromatography: past, present and future. J. Biochem. Biophys. Methods, 2001, 49(1-3), 313-334.
131. Gutierrez, R.; del Valle, E. M. M.; Galan, M. A. Immobilized metalion affinity chromatography: Status and trends. Sep. Purif. Rev., 2007, 36 1, 71-111.
132. Zatloukalova, E. Immobilized Metal Ion Affinity Chromatography and its Application. Chem. Listy, 2004, 98 5, 254-259.
133. Bi, X. Y.; Agarwal, A.; Yang, K. L. Oligopeptide-modified silicon nanowire arrays as multichannel metal ion sensors. Biosens. Bioelectron., 2009, 24 11, 3248-3251.
134. Joshi, B. P.; Park, J.; Lee, W. I.; Lee, K. H. Ratiometric and turn-on monitoring for heavy and transition metal ions in aqueous solution with a fluorescent peptide sensor. Talanta, 2009, 78 3, 903-909.
135. Wang, C. K.; Wang, J. E.; Liu, D. J.; Wang, Z. X. Gold nanoparticlebased colorimetric sensor for studying the interactions of betaamyloid peptide with metallic ions. Talanta, 2010, 80 5, 1626-1631.
136. Wang, F. D.; Kim, B. E.; Petris, M. J.; Eide, D. J. The mammalian Zip5 protein is a zinc transporter that localizes to the basolateral surface of polarized cells. J. Biol. Chem., 2004, 279 49, 51433-51441.
137. Gutteridge, J. M. C.; Richmond, R.; Halliwell, B. Oxygen Free-Radicals and Lipid-Peroxidation - Inhibition by the Protein Ceruloplasmin. FEBS Lett., 1980, 112 2, 269-272.
138. Moriya, M.; Ho, Y. H.; Grana, A.; Nguyen, L.; Alvarez, A.; Jamil, R.; Ackland, M. L.; Michalczyk, A.; Hamer, P.; Ramos, D.; Kim, S.; Mercer, J. F. B.; Linder, M. C. Copper is taken up efficiently from albumin and alpha (2)-macroglobulin by cultured human cells by more than one mechanism. Am. J. Physiol. Cell Physiol., 2008, 295 3, C708-C721.
139. Sanchez, L.; Calvo, M.; Brock, J. H. Biological Role of Lactoferrin. Arch. Dis. Child., 1992, 67 5, 657-661.
140. Bernal, V.; Jelen, P. Thermal-Stability of Whey Proteins - a Calorimetric Study. J. Dairy Sci., 1985, 68 11, 2847-2852.
141. Ghoshal, K.; Jacob, S. T. Regulation of metallothionein gene expression. Prog. Nucleic Acid Res. Mol. Biol., 2001, 66, 357-384.
142. Gunes, C.; Heuchel, R.; Georgiev, O.; Muller, K. H.; Lichtlen, P.; Bluthmann, H.; Marino, S.; Aguzzi, A.; Schaffner, W. Embryonic lethality and liver degeneration in mice lacking the metalresponsive transcriptional activator MTF-1. Embo J., 1998, 17 10, 2846-2854.
143. Klassen, R. B.; Crenshaw, K.; Kozyraki, R.; Verroust, P. J.; Tio, L.; Atrian, S.; Allen, P. L.; Hammond, T. G. Megalin mediates renal uptake of heavy metal metallothionein complexes. Am. J. Physiol. Renal Physiol., 2004, 287 3, F393-F403.
144. Culotta, V. C.; Hamer, D. H. Fine Mapping of a Mouse Metallothionein Gene Metal Response Element. Mol. Cell. Biol., 1989, 9 3, 1376-1380.
145. Searle, P. F.; Stuart, G. W.; Palmiter, R. D. Building a Metal-Responsive Promoter with Synthetic Regulatory Elements. Mol. Cell. Biol., 1985, 5 6, 1480-1489.
146. Valko, M.; Morris, H.; Cronin, M. T. D. Metals, toxicity and oxidative stress. Curr. Med. Chem., 2005, 12 10, 1161-1208.
147. Harrison, P. M.; Arosio, P. Ferritins: Molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta Bioenerg., 1996, 1275 3, 161-203.
148. Kozlenkov, A.; Manes, T.; Hoylaerts, M. F.; Millan, J. L. Function assignment to conserved residues in mammalian alkaline phosphatases. J. Biol. Chem., 2002, 277 25, 22992-22999.
149. Barondeau, D. P.; Kassman, C. J.; Bruns, C. K.; Tainer, J. A.; Getzoff, E. D. Nickel superoxide dismutase structure and mechanism. Protein Sci., 2004, 13 (431).
150. Muller, F. L.; Lustgarten, M. S.; Jang, Y.; Richardson, A.; Van Remmen, H. Trends in oxidative aging theories. Free Radic. Biol. Med., 2007, 43 4, 477-503.
151. Puente, X. S.; Sanchez, L. M.; Overall, C. M.; Lopez-Otin, C. Human and mouse proteases: A comparative genomic approach. Nat. Rev. Genet., 2003, 4 7, 544-558.
152. Dhanaraj, V.; Ye, Q. Z.; Johnson, L. L.; Hupe, D. J.; Ortwine, D. F.; Dubar, J. B.; Rubin, J. R.; Pavlovsky, A.; Humblet, C.; Blundell, T. L. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure, 1996, 4 4, 375-386.
153. Konigsberg, W.; Hill, R. J. Structure of Human Hemoglobin. 3. Sequence of Amino Acids in Tryptic Peptides of Alpha Chain. J. Biol. Chem., 1962, 237 8, 2547-2561.
154. Giljohann, D. A.; Mirkin, C. A. Drivers of biodiagnostic development. Nature, 2009, 462 7272, 461-464.
155. Mirkin, C. A.; Letsinger, R. L.; Mucic, R. C.; Storhoff, J. J. A DNAbased method for rationally assembling nanoparticles into macroscopic materials. Nature, 1996, 382 6592, 607-609.
156. Mirkin, C. A.; Taton, T. A. Materials chemistry - Semiconductors meet biology. Nature, 2000, 405 6787, 626-627.
157. Rosi, N. L.; Giljohann, D. A.; Thaxton, C. S.; Lytton-Jean, A. K. R.; Han, M. S.; Mirkin, C. A. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science, 2006, 312 5776, 1027-1030.
158. Marchal, F.; Pic, E.; Pons, T.; Dubertret, B.; Bolotine, L.; Guillemin, F. Quantum dots in oncological surgery: the future for surgical margin status? Bull Cancer, 2008, 95 12, 1149-1153.
159. Zheng, G. F.; Patolsky, F.; Cui, Y.; Wang, W. U.; Lieber, C. M. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat. Biotechnol., 2005, 23 10, 1294-1301.
160. Huska, D.; Hubalek, J.; Adam, V.; Kizek, R. Miniaturized electrochemical detector as a tool for detection of DNA amplified by PCR. Electrophoresis, 2008, 29 24, 4964-4971.
161. Huska, D.; Hubalek, J.; Adam, V.; Vajtr, D.; Horna, A.; Trnkova, L.; Havel, L.; Kizek, R. Automated nucleic acids isolation using paramagnetic microparticles coupled with electrochemical detection. Talanta, 2009, 79 2, 402-411.
162. Adam, V.; Petrlova, J.; Wang, J.; Eckschlager, T.; Trnkova, L.; Kizek, R. Zeptomole electrochemical detection of metallothioneins. PLoS One, 2010, 5 7, e11441.
163. Sahoo, S. K.; Parveen, S.; Panda, J. J. The present and future of nanotechnology in human health care. Nanomed. Nanotechnol. Biol. Med., 2007, 3 1, 20-31.
164. Patra, C. R.; Bhattacharya, R.; Mukhopadhyay, D.; Mukherjee, P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv. Drug Deliv. Rev., 2010, 62 3, 346-361.
165. Gu, F. X.; Karnik, R.; Wang, A. Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R. S.; Farokhzad, O. C. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2 3, 14-21.
166. Chomoucka, J.; Drbohlavova, J.; Huska, D.; Adam, V.; Kizek, R.; Hubalek, J. Magnetic nanoparticles and targeted drug delivering. Pharmacol. Res., 2010, 62 2, 144-149.
167. Wang, J. Q.; Sui, M. H.; Fan, W. M. Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics. Curr. Drug Metab., 2010, 11 2, 129-141.
168. Adiseshaiah, P. P.; Hall, J. B.; McNeil, S. E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2010, 2 1, 99-112.
169. Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer, 2005, 5 3, 161-171.
170. Juillerat-Jeanneret, L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drugnanoparticles? Drug Discov. Today, 2008, 13(23-24), 1099-1106.
171. Cho, K. J.; Wang, X.; Nie, S. M.; Chen, Z.; Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14 5, 1310-1316.
172. Mishra, B.; Patel, B. B.; Tiwari, S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomed. Nanotechnol. Biol. Med., 2010, 6 1, 9-24.
173. Peer, D.; Karp, J. M.; Hong, S.; FaroKhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2 12, 751-760.
174. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. Semin. Orig. Investig., 2008, 26 1, 57-64.
175. Puri, A.; Loomis, K.; Smith, B.; Lee, J. H.; Yavlovich, A.; Heldman, E.; Blumenthal, R. Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic. Crit. Rev. Ther. Drug Carr. Syst., 2009, 26 6, 523-580.
176. Garrido, C.; Aliaga, A. E.; Gomez-Jeria, J. S.; Clavijo, R. E.; Campos-Vallette, M. M.; Sanchez-Cortes, S. Adsorption of oligopeptides on silver nanoparticles: surface-enhanced Raman scattering and theoretical studies. J. Raman Spectrosc., 2010, 41 10, 1149-1155.
177. Graf, P.; Mantion, A.; Foelske, A.; Shkilnyy, A.; Masic, A.; Thunemann, A. E.; Taubert, A. Peptide-Coated Silver Nanoparticles: Synthesis, Surface Chemistry, and pH-Triggered, Reversible Assembly into Particle Assemblies. Chem. Eur. J., 2009, 15 23, 5831-5844.
178. Cheng, W.; Chen, Y. L.; Yan, F.; Ding, L.; Ding, S. J.; Ju, H. X.; Yin, Y. B. Ultrasensitive scanometric strategy for detection of matrix metalloproteinases using a histidine tagged peptide-Au nanoparticle probe. Chem. Commun., 2011, 47 10, 2877-2879.
179. Slocik, J. M.; Zabinski, J. S.; Phillips, D. M.; Naik, R. R. Colorimetric response of peptide-functionalized gold nanoparticles to metal ions. Small, 2008, 4 5, 548-551.
180. Yadav, S. C.; Kumari, A.; Yadav, R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides, 2011, 32 1, 173-187.
181. Bolhassani, A.; Safaiyan, S.; Rafati, S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer, 2011, 10 3, 1476-4598.
182. Obonyo, O.; Fisher, E.; Edwards, M.; Douroumis, D. Quantum dots synthesis and biological applications as imaging and drug delivery systems. Crit. Rev. Biotechnol., 2010, 30 4, 283-301.
183. Jain, K. K. Advances in the field of nanooncology. BMC Med., 2010, 8 83, 1741-7015.
184. Murray, C. B.; Kagan, C. R.; Bawendi, M. G. Synthesis and characterization of monodisperse nanocrystals and close-packed nanocrystal assemblies. Annu. Rev. Mater. Sci., 2000, 30, 545-610.
185. Singh, A.; Sharma, P.; Brown, S.; Moudgil, B. Luminescent and Magnetic Nanoparticulates as Biomarkers. KONA Powder Part. J., 2010, (28), 20-37.
186. Jain, K. K. The Role of Nanobiotechnology in the Development of Personalized Medicine. Med. Princ. Pract., 2011, 20 1, 1-3.
187. Wang, Y. Z.; Yu, L.; Han, L. M.; Sha, X. Y.; Fang, X. L. Difunctional Pluronic copolymer micelles for paclitaxel delivery: Synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int. J. Pharm., 2007, 337(1-2), 63-73.
188. Nelson, D. L.; Kennedy, E. P. Transport of magnesium by a repressible and a nonrepressible system in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A., 1972, 69 5, 1091-1093.
189. Ratte, H. T. Bioaccumulation and toxicity of silver compounds: A review. Environ. Toxicol. Chem., 1999, 18 1, 89-108.
190. Lansdown, A. B. G. Critical observations on the neurotoxicity of silver. Crit. Rev. Toxicol., 2007, 37 3, 237-250.
191. Panyala, N. R.; Pena-Mendez, E. M.; Havel, J. Silver or silver nanoparticles: a hazardous threat to the environment and human health? J. Appl. Biomed., 2008, 6 3, 117-129.
192. Ratnaike, R. N. Acute and chronic arsenic toxicity. Postgrad. Med. J., 2003, 79 933, 391-396.
193. Mandal, B. K.; Suzuki, K. T. Arsenic round the world: a review. Talanta, 2002, 58 1, 201-235.
194. Preuss, O.; Oster, H. The modern view of beryllium toxicity. Arbeitsmed. Sozialmed. Praventivmed., 1980, 15 11, 270-275.
195. Marchand-Adam, S.; Guillon, F.; Brauner, M.; Valeyre, D. Chronic beryllium disease: A model of interaction between environmental exposure and genetic predisposition. Pathogenesis and clinical features (Part 2). Rev. Mal. Respir., 2005, 22 2, 271-287.
196. Mederos, A.; Dominguez, S.; Chinea, E.; Brito, F.; Cecconi, F. Review: new advances in the coordination chemistry of the beryllium (II). J. Coord. Chem., 2001, 53 3, 191-222.
197. Strupp, C. Beryllium Metal II. A Review of the Available Toxicity Data. Ann. Occup. Hyg., 2011, 55 1, 43-56.
198. Slikkerveer, A.; Dewolff, F. A. Pharmacokinetics and toxicity of bismuth compounds. Med. Toxicol. Adver. Drug Exp., 1989, 4 5, 303-323.
199. Winship, K. A. Toxicity of bismuth salts. Adverse Drug React. Toxicol. Rev., 1983, 2 2, 103-121.
200. Bradley, B.; Singleton, M.; Po, A. L. W. Bismuth toxicity - A reassessment. J. Clin. Pharm. Ther., 1989, 14 6, 423-441.
201. Stohs, S. J.; Bagchi, D. Oxidative mechanisms in the toxicity of metal-ions. Free Radic. Biol. Med., 1995, 18 2, 321-336.
202. Domingo, J. L. Metal-induced developmental toxicity in mammals - a review. J. Toxicol. Environ. Health, 1994, 42 2, 123-141.
203. Neathery, M. W.; Miller, W. J. Metabolism and toxicity of cadmium, mercury, and lead in animals - review. J. Dairy Sci., 1975, 58 12, 1767-1781.
204. Lazarus, M. Cadmium and selenium interaction in mammals. Arh. Hig. Rada. Toksikol., 2010, 61 3, 357-369.
205. Matovic, V.; Buha, A.; Bulat, Z.; Dukic-Cosic, D. Cadmium toxicity revisited: Focus on oxidative stress induction and interactions with zinc and magnesium. Arh. Hig. Rada. Toksikol., 2011, 62 1, 65-76.
206. Barceloux, D. G. Cobalt. J. Toxicol. Clin. Toxicol., 1999, 37 2, 201-216.
207. Lison, D. Human toxicity of cobalt-containing dust and experimental studies on the mechanism of interstitial lung disease (hard metal disease). Crit. Rev. Toxicol., 1996, 26 6, 585-616.
208. Sunderman, F. W. Review: Nasal toxicity, carcinogenicity, and olfactory uptake of metals. Ann. Clin. Lab. Sci., 2001, 31 1, 3-24.
209. Cohen, M. D.; Kargacin, B.; Klein, C. B.; Costa, M. Mechanisms of chromium carcinogenicity and toxicity. Crit. Rev. Toxicol., 1993, 23 3, 255-281.
210. Costa, M. Toxicity and carcinogenicity of Cr (VI) in animal models and humans. Crit. Rev. Toxicol., 1997, 27 5, 431-442.
211. Costa, M.; Klein, C. B. Toxicity and carcinogenicity of chromium compounds in humans. Crit. Rev. Toxicol., 2006, 36 2, 155-163.
212. Gaetke, L. M.; Chow, C. K. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology, 2003, 189(1-2), 147-163.
213. Flemming, C. A.; Trevors, J. T. Copper toxicity and chemistry in the environment - a review. Water Air Soil Pollut., 1989, 44(1-2), 143-158.
214. Linder, M. C.; HazeghAzam, M. Copper biochemistry and molecular biology. Am. J. Clin. Nutr., 1996, 63 5, S797-S811.
215. Theophanides, T.; Anastassopoulou, J. Copper and carcinogenesis. Crit. Rev. Oncol. Hematol., 2002, 42 1, 57-64.
216. Papanikolaou, G.; Pantopoulos, K. Iron metabolism and toxicity. Toxicol. Appl. Pharmacol., 2005, 202 2, 199-211.
217. Emerit, J.; Beaumont, C.; Trivin, F. Iron metabolism, free radicals, and oxidative injury. Biomed. Pharmacother., 2001, 55 6, 333-339.
218. Porter, J. B. Practical management of iron overload. Br. J. Haematol., 2001, 115 2, 239-252.
219. Fubini, B.; Arean, C. O. Chemical aspects of the toxicity of inhaled mineral dusts. Chem. Soc. Rev., 1999, 28 6, 373-381.
220. Koos, B. J.; Longo, L. D. Mercury toxicity in pregnant woman, fetus, and newborn-infant - review. Am. J. Obstet. Gynecol., 1976, 126 3, 390-409.
221. Langford, N. J.; Ferner, R. E. Toxicity of mercury. J. Hum. Hypertens., 1999, 13 10, 651-656.
222. Magos, L.; Clarkson, T. W. Overview of the clinical toxicity of mercury. Ann. Clin. Biochem., 2006, 43, 257-268.
223. Zahir, F.; Rizwi, S. J.; Haq, S. K.; Khan, R. H. Low dose mercury toxicity and human health. Environ. Toxicol. Pharmacol., 2005, 20 2, 351-360.
224. Crossgrove, J.; Zheng, W. Manganese toxicity upon overexposure. NMR Biomed., 2004, 17 8, 544-553.
225. Butterworth, R. F.; Spahr, L.; Fontaine, S.; Layrargues, G. P. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab. Brain Dis., 1995, 10 4, 259-267.
226. Gerber, G. B.; Leonard, A.; Hantson, P. Carcinogenicity, mutagenicity and teratogenicity of manganese compounds. Crit. Rev. Oncol. Hematol., 2002, 42 1, 25-34.
227. Erikson, K. M.; Thompson, K.; Aschner, J.; Aschner, M. Manganese neurotoxicity: A focus on the neonate. Pharmacol. Ther., 2007, 113 2, 369-377.
228. Keen, C. L.; Ensunsa, J. L.; Clegg, M. S. In Metal Ions in Biological Systems, Marcel Dekker: New York, 2000; Vol. 37, pp 89-121.
229. Coogan, T. P.; Latta, D. M.; Snow, E. T.; Costa, M. Toxicity and carcinogenicity of nickel compounds. Crc. Crit. Rev. Toxicol., 1989, 19 4, 341-384.
230. Denkhaus, E.; Salnikow, K. Nickel essentiality, toxicity, and carcinogenicity. Crit. Rev. Oncol. Hematol., 2002, 42 1, 35-56.
231. Barceloux, D. G. Nickel. J. Toxicol. Clin. Toxicol., 1999, 37 2, 239-258.
232. Hirano, S.; Suzuki, K. T. Exposure, metabolism, and toxicity of rare earths and related compounds. Environ. Health Perspect., 1996, 104, 85-95.
233. Patrick, L. Lead toxicity part II: The role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Altern. Med. Rev., 2006, 11 2, 114-127.
234. Sundar, S.; Chakravarty, J. Antimony Toxicity. Int. J. Environ. Res. Public Health, 2010, 7 12, 4267-4277.
235. Gebel, T. Arsenic and antimony: comparative approach on mechanistic toxicology. Chem. Biol. Interact., 1997, 107 3, 131-144.
236. Winship, K. A. Toxicity of antimony and its compounds. Adverse Drug React. Toxicol. Rev., 1987, 6 2, 67-90.
237. Winship, K. A. Toxicity of tin and its compounds. Adverse Drug React. Toxicol. Rev., 1988, 7 1, 19-38.
238. Trabucco, A.; Di Pietro, P.; Nori, S. L.; Fulceri, F.; Fumagalli, L.; Paparelli, A.; Fornai, F. Methylated tin toxicity a reappraisal using rodents models. Arch. Ital. Biol., 2009, 147 4, 141-153.
239. Peter, A. L. J.; Viraraghavan, T. Thallium: a review of public health and environmental concerns. Environ. Int., 2005, 31 4, 493-501.
240. Cvjetko, P.; Cvjetko, I.; Pavlica, M. Thallium toxicity in humans. Arh. Hig. Rada. Toksikol., 2010, 61 1, 111-119.
241. Ibrahim, D.; Froberg, B.; Wolf, A.; Rusyniak, D. E. Heavy metal poisoning: Clinical presentations and pathophysiology. Clin. Lab. Med., 2006, 26 1, 67-97.
242. Galvan-Arzate, S.; Santamaria, A. Thallium toxicity. Toxicol. Lett., 1998, 99 1, 1-13.
243. Leonard, A.; Gerber, G. B. Mutagenicity, carcinogenicity and teratogenicity of thallium compounds. Mutat. Res.-Rev. Mutat. Res., 1997, 387 1, 47-53.
244. Mulkey, J. P.; Oehme, F. W. A review of thallium toxicity. Vet. Human Toxicol., 1993, 35 5, 445-453.
245. Barceloux, D. G. Vanadium. J. Toxicol. Clin. Toxicol., 1999, 37 2, 265-278.
246. Domingo, J. L. Vanadium: A review of the reproductive and developmental toxicity. Reprod. Toxicol., 1996, 10 3, 175-182.
247. Assem, F. L.; Levy, L. S. A review of current toxicological concerns on vanadium pentoxide and other vanadium compounds: gaps in knowledge and directions for future research. J. Toxicol. Env. Health B Crit. Rev., 2009, 12 4, 289-306.
248. Maret, W.; Sandstead, H. H. Zinc requirements and the risks and benefits of zinc supplementation. J. Trace Elem. Med. Biol., 2006, 20 1, 3-18.
249. Cai, L.; Li, X. K.; Song, Y.; Cherian, M. G. Essentiality, toxicology and chelation therapy of zinc and copper. Curr. Med. Chem., 2005, 12 23, 2753-2763.
250. Roberts, E. A. Zinc Toxicity: From "No, Never" to "Hardly Ever". Gastroenterol., 2011, 140 4, 1132-1135.
251. Abdelmageed, A. B.; Oehme, F. A review of the biochemical roles, toxicity and interactions of zinc, copper and iron. 3. iron. Vet. Human Toxicol., 1990, 32 4, 324-328.
252. Rout, G. R.; Das, P. Effect of metal toxicity on plant growth and metabolism: I. Zinc. Agronomie, 2003, 23 1, 3-11.